https://www.selleckchem.com/products/pamapimod-r-1503-ro4402257.html All identified bone and extraskeletal lesions, except for a brain lesion in 1 patient, were FDG-avid. In 6 of 20 patients (30%) with available prior CT or MRI, PET/CT demonstrated additional RDD lesions (bones n = 5, pleura n = 1) that were not apparent on anatomic imaging; 3 of these lesions were outside the CT field of view, and 3 were not recognized on CT. Overall, 13 of 109 PET/CT scans led to a change in management, affecting 41% (11/27) of patients. CONCLUSION FDG PET/CT was valuable in defining disease extent and optimizing treatment strategy in patients with RDD.The chief medical officer (CMO) is a key member of the administration of most large health care systems. The CMO helps with communication between the medical staff and the nonphysician administrators. The CMO typically plays an important role in utilization review, ensuring compliance with laws and regulations, peer review, credentialing, and privileging. One of the most important roles of the CMO has been to improve quality and safety while keeping costs under control, although now many institutions also have quality and safety officers. In addition, the CMO plays a major role in advising the administration regarding clinical equipment purchases, including those for emerging technologies, and in long-range clinical planning.BACKGROUND Repair of the soft tissue defect in myelomeningoceles remains challenging. The literature currently lacks a systematic approach, reporting high rates of complications. We present outcomes from the largest series to date and describe a simplified approach that minimizes morbidity and streamlines decision making. METHODS Patients 1 year or younger who underwent myelomeningocele repair between 2008 and 2018 were reviewed. Flap types were categorized by tissue composition. Complications were dichotomized into early and late (30 days postoperative, respectively). Logistic regression was used to measure the